Graft versus host disease (GVHD) in acute and chronic forms is a frequent post-transplant complication and seen in 50% of patients in acute and up to 70% cases in chronic GVHD setting. Patients with multiorgan involvement and those who are steroid refractory, frequently present with complications arising from this post-transplant complication. These GVHD patients are frequently managed in the Intensive care unit for treatment of air leaks, effusions, management of hypoxemia due to lung GVHD or infections. Close coordination between hematologists and Pulmonary medicine specialists is critical for timely management of these complications to improve patient outcomes.
KanateASMajhailNSSavaniBN, et al.Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2020;26(7):1247-1256.
2.
HeybatiKOchalDHoganW, et al.Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipients. Ann Hematol. 2024;103(3):957-967.
3.
LeeSJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30-37.
4.
SchoemansHMLeeSJFerraraJL, et al.EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant.2018;53(11):1401-1415.
5.
GreinixHTEikemaDJKosterL, et al.Incidence of acute graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation over time: A study from the transplant complications and chronic malignancies working party of the EBMT. Blood. 2018;132(Supplement 1):2120-2120.
6.
PidalaJKurlandBChaiX, et al.Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: Report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651-4657.
7.
HamiltonBK. Updates in chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2021;2021(1):648-654.
8.
McDonaldGBSandmaierBMMielcarekM, et al.Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: Comparing 2003–2007 versus 2013–2017 cohorts. Ann Intern Med. 2020;172(4):229-239.
9.
LeeSJNguyenTDOnstadL, et al.Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(3):555-562.
10.
SaillardCCrocchioloRFurstS, et al.National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma. 2014;55(5):1106-1112.
11.
AtkinsonKHorowitzMMGaleRP, et al.Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75(12):2459-2464.
12.
GooleyTAChienJWPergamSA, et al.Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med.2010;363(22):2091-2101.
13.
D'SouzaAFrethamCLeeSJ, et al.Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26(8):e177-e182.
14.
AraiSAroraMWangT, et al.Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: A report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266-274.
15.
LeeSJKimHTHoVT, et al.Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant.2006;38(4):305-310.
16.
YuJLalLSAndersonA, et al.Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: A retrospective claims database analysis. Curr Med Res Opin. 2021;37(5):755-759.
17.
LueckCTzalavrasAWohlfarthP, et al.Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant. 2023;58(3):303-310.
18.
ZeiserRBlazarBR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565-2579.
19.
SullivanKMShulmanHMStorbR, et al.Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57(2):267-276.
20.
FilipovichAHWeisdorfDPavleticS, et al.National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
21.
JagasiaMHGreinixHTAroraM, et al.National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1.
22.
PidalaJKimJAnasettiC, et al.The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011;96(11):1678-1684.
23.
ZhaoDYoungJSChenYH, et al.Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease. J Immunol. 2011;186(2):856-868.
24.
WilhelmKGanesanJMüllerT, et al.Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16(12):1434-1438.
25.
AllenJLTataPVForeMS, et al.Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014;123(13):2108-2115.
26.
YoungJSWuTChenY, et al.Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol. 2012;189(1):222-233.
27.
SrinivasanMFlynnRPriceA, et al.Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570-1580.
28.
SakodaYHashimotoDAsakuraS, et al.Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007;109(4):1756-1764.
29.
ForcadeEPazKFlynnR, et al.An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI insight. 2017;2(12):1–15.
30.
StorbRDeegHJWhiteheadJ, et al.Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729-735.
31.
CutlerCLoganBNakamuraR, et al.Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372-1377.
32.
PerkinsJFieldTKimJ, et al.A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010;16(7):937-947.
33.
RodriguezRNakamuraRPalmerJM, et al.A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(5):1098-1105.
34.
SalhotraAHuiSYangD, et al.Long-Term outcomes of patients with acute myelogenous leukemia treated with myeloablative fractionated total body irradiation TBI-based conditioning with a tacrolimus- and sirolimus-based graft-versus-host disease prophylaxis regimen: 6-year follow-up from a single center. Biol Blood Marrow Transplant. 2020;26(2):292-299.
35.
KrögerNSolanoCWolschkeC, et al.Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med.2016;374(1):43-53.
36.
BleakleyMHeimfeldSLoebKR, et al.Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest. 2015;125(7):2677-2689.
37.
PieriniARuggeriLCarottiA, et al.Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv. 2021;5(5):1199-1208.
38.
MeyerEHLaportGXieBJ, et al.Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight. 2019;4(10):2338–2348.
39.
Bolaños-MeadeJHamadaniMWuJ, et al.Post-Transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med.2023;388(25):2338-2348.
40.
WatkinsBQayedMMcCrackenC, et al.Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol. 2021;39(17):1865-1877.
41.
McDonaldGB. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127(12):1544-1550.
42.
FlowersMEDMartinPJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606-615.
43.
MielcarekMFurlongTStorerBE, et al.Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: A randomized controlled trial. Haematologica. 2015;100(6):842-848.
44.
Major-MonfriedHRenteriaASPawarodeA, et al.MAGIC Biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131(25):2846-2855.
45.
MacMillanMLRobinMHarrisAC, et al.A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767.
46.
ZeiserRvon BubnoffNButlerJ, et al.Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med.2020;382(19):1800-1810.
47.
CutlerCLeeSJAraiS, et al.Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: The ROCKstar study. Blood. 2021;138(22):2278-2289.
48.
MiklosDCutlerCSAroraM, et al.Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243-2250.
49.
ZeiserRPolverelliNRamR, et al.Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med.2021;385(3):228-238.
DitschkowskiMElmaagacliAHKoldehoffM, et al.Bronchiolitis obliterans after allogeneic hematopoietic SCT: Further insight–new perspectives?Bone Marrow Transplant. 2013;48(9):1224-1229.
52.
AstashchankaARyanJLinE, et al.Pulmonary Complications in Hematopoietic Stem Cell Transplant Recipients-A Clinician Primer. J Clin Med. 2021;10(15):1–20.
53.
WilliamsKM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129(4):448-455.
54.
ChienJWDuncanSWilliamsKM, et al.Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S106-S114.
55.
HansenJESunXGWassermanK. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest. 2007;131(2):349-355.
56.
TizonRFreyNHeitjanDF, et al.High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant. 2012;47(10):1332-1337.
57.
ChengGSStorerBChienJW, et al.Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant. Ann Am Thorac Soc. 2016;13(11):1932-1939.
58.
KwokWCLiangB-MLuiMM, et al.Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. Respirology. 2019;24(5):459-466.
59.
de JongPADoddJDCoxsonHO, et al.Bronchiolitis obliterans following lung transplantation: Early detection using computed tomographic scanning. Thorax. 2006;61(9):799-804.
60.
VerledenSEVosRVanaudenaerdeBM, et al.Chronic lung allograft dysfunction phenotypes and treatment. J Thorac Dis. 2017;9(8):2650-2659.
61.
BrockmannJGBroeringDCRazaSM, et al.Solid organ transplantation following allogeneic haematopoietic cell transplantation: Experience from a referral organ transplantation center and systematic review of literature. Bone Marrow Transplant. 2019;54(2):190-203.
62.
GlanvilleARBendenCBergeronA, et al.Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. ERJ Open Res. 2022;8(3):1–16.
63.
RuttensDVerledenSEVandermeulenE, et al.Prophylactic azithromycin therapy after lung transplantation: Post hoc analysis of a randomized controlled trial. Am J Transplant. 2016;16(1):254-261.
64.
BergeronAChevretSGranataA, et al.Effect of azithromycin on airflow decline–free survival after allogeneic hematopoietic stem cell transplant: The ALLOZITHRO randomized clinical trial. JAMA. 2017;318(6):557-566.
65.
WilliamsKMChengG-SPusicI, et al.Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710-716.
66.
BergeronAChevretSChagnonK, et al.Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191(11):1242-1249.
67.
YanikGAMineishiSLevineJE, et al.Soluble tumor necrosis factor receptor: Enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(7):1044-1054.
68.
SalhotraASandhuKO’HearnJ, et al.A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease. Expert Rev Clin Immunol. 2023;19(3):241-251.
69.
ZhangXZhaoXShenY, et al.Ruxolitinib as an effective and steroid-sparing first-line treatment in newly diagnosed BOS patients after hematopoietic stem cell transplantation. Front Pharmacol. 2022;13(13):916472.
70.
KitkoCLAroraMDeFilippZ, et al.Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: Results of a phase I/II study. J Clin Oncol. 2023;41(10):1864-1875.
71.
AkpekGLeeSMAndersV, et al.A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7(9):495-502.
72.
AllareddyVRoyARampaS, et al.Outcomes of stem cell transplant patients with acute respiratory failure requiring mechanical ventilation in the United States. Bone Marrow Transplant. 2014;49(10):1278-1286.
73.
YadavHNolanMEBohmanJK, et al.Epidemiology of acute respiratory distress syndrome following hematopoietic stem cell transplantation. Crit Care Med. 2016;44(6):1082-1090.
74.
Garcia BorregaJHegerJ-MKoehlerP, et al.Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospital. Ann Hematol. 2022;101(2):389-395.
75.
FinanMPastoresSM. Acute respiratory failure after hematopoietic stem cell transplantation. In: EsquinasAMPravinkumarSESoubaniAO, eds. Mechanical Ventilation in Critically Ill Cancer Patients: Rationale and Practical Approach. Springer International Publishing; 2018:347-354.
76.
HilbertGGrusonDVargasF, et al.Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 2001;344(7):481-487.
77.
NeuschwanderALemialeVDarmonM, et al.Noninvasive ventilation during acute respiratory distress syndrome in patients with cancer: Trends in use and outcome. J Crit Care. 2017;38(4):295-299.
78.
CarteauxGMillán-GuilarteTDe ProstN, et al.Failure of noninvasive ventilation for De Novo acute hypoxemic respiratory failure: Role of tidal volume. Crit Care Med. 2016;44(2):282-290.
79.
LemialeVResche-RigonMMokartD, et al.Acute respiratory failure in patients with hematological malignancies: Outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en reanimation onco-hematologique (Grrr-OH) study. Ann Intensive Care. 2015;5(1):28.
80.
GilbertCVasuTSBaramM. Use of mechanical ventilation and renal replacement therapy in critically ill hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2013;19(2):321-324.
81.
ElbahlawanLSrinivasanAMorrisonRR. A critical care and transplantation-based approach to acute respiratory failure after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant. 2016;22(4):617-626.
82.
ChatterjeeSRobertsBAhluwaliaAK, et al.Integrating narrative goals of care in the medical intensive care unit: Impact on educational and clinical outcomes. ATS Sch. 2022;3(3):449-459.
83.
Aguilar-GuisadoMJiménez-JambrinaMEspigadoI, et al.Pneumonia in allogeneic stem cell transplantation recipients: A multicenter prospective study. Clin Transplant. 2011;25(6):E629-E638.
84.
PatelNRLeePSKimJH, et al.The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients. Chest. 2005;127(4):1388-1396.
85.
BrownbackKRSimpsonSQ. Association of bronchoalveolar lavage yield with chest computed tomography findings and symptoms in immunocompromised patients. Ann Thorac Med. 2013;8(3):153-159.
86.
ShannonVRAnderssonBSLeiX, et al.Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(4):647-655.
87.
O'DwyerDNDuvallASXiaM, et al.Transbronchial biopsy in the management of pulmonary complications of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53(2):193-198.
88.
ChellapandianDLehrnbecherTPhillipsB, et al.Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: A systematic review and meta-analysis. J Clin Oncol. 2015;33(5):501-509.
89.
BauerPRChevretSYadavH, et al.Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy. Eur Respir J. 2019;54(1):1–11.
90.
BurgerCD. Utility of positive bronchoalveolar lavage in predicting respiratory failure after hematopoietic stem cell transplantation: A retrospective analysis. Transplant Proc. 2007;39(5):1623-1625.
91.
DunaganDPBakerAMHaponikEF, et al.Bronchoscopic evaluation of pulmonary infiltrates following bone marrow transplantation. Chest. 1997;111(1):135-141.
92.
HofmeisterCCCzerlanisCForsytheS, et al.Retrospective utility of bronchoscopy after hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38(10):693-698.
93.
FeinsteinMBMokhtariMFerreiroR, et al.Fiberoptic bronchoscopy in allogeneic bone marrow transplantation: Findings in the era of serum cytomegalovirus antigen surveillance. Chest. 2001;120(4):1094-1100.
94.
GrusonDHilbertGValentinoR, et al.Utility of fiberoptic bronchoscopy in neutropenic patients admitted to the intensive care unit with pulmonary infiltrates. Crit Care Med. 2000;28(7):2224-2230.
95.
PeikertTRanaSEdellES. Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. Mayo Clin Proc. 2005;80(11):1414-1420.
96.
KatsumataYTeradaJAbeM, et al.An analysis of the clinical benefit of 37 bronchoalveolar lavage procedures in patients with hematologic disease and pulmonary complications. Intern Med. 2019;58(8):1073-1080.
97.
KimSWRheeCKKangHS, et al.Diagnostic value of bronchoscopy in patients with hematologic malignancy and pulmonary infiltrates. Ann Hematol. 2015;94(1):153-159.
98.
BissingerALEinseleHHamprechtK, et al.Infectious pulmonary complications after stem cell transplantation or chemotherapy: Diagnostic yield of bronchoalveolar lavage. Diagn Microbiol Infect Dis. 2005;52(4):275-280.
99.
AzoulayEMokartDRabbatA, et al.Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: Prospective multicenter data. Crit Care Med. 2008;36(1):100-107.
100.
BerginSPChemalyRFDuttaguptaR, et al.544. PICKUP: Pneumonia in the immunocompromised - use of the karius test for detection of undiagnosed pathogens. Open Forum Infect Dis.2022;9(Supplement_2):153–159.
101.
KubiakJMorganAKirmaierA, et al.Universal PCR for bacteria, mycobacteria, and fungi: A 10-year retrospective review of clinical indications and patient outcomes. J Clin Microbiol.2023;61(1):2023.08.02.23293145.
102.
AgrawalAHogarthDKMurguS. Robotic bronchoscopy for pulmonary lesions: A review of existing technologies and clinical data. J Thorac Dis. 2020;12(6):3279-3286.
103.
VogelMBrodoefelHBethgeW, et al.Spontaneous thoracic air-leakage syndrome in patients following allogeneic hematopoietic stem cell transplantation: Causes, CT-follow up and patient outcome. Eur J Radiol. 2006;60(3):392-397.
MacDuffAArnoldAHarveyJ. Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii18-ii31.
106.
BaumannMHStrangeCHeffnerJE, et al.Management of spontaneous pneumothorax: An American College of Chest Physicians Delphi consensus statement. Chest. 2001;119(2):590-602.
107.
DuganKCLaxmananBMurguS, et al.Management of persistent air leaks. Chest. 2017;152(2):417-423.
108.
BermeaRSMillerJWilsonWW, et al.One-Way endobronchial valves as management for persistent air leaks: A preview of what's to come?Am J Respir Crit Care Med. 2019;200(10):1318-1320.
109.
FiorelliAD’AndrilliACasconeR, et al.Unidirectional endobronchial valves for management of persistent air-leaks: Results of a multicenter study. J Thorac Dis. 2018;10(11):6158-6167.
110.
NoblePW. The pulmonary complications of bone marrow transplantation in adults. West J Med. 1989;150(4):443-449.
111.
ModiDJangHKimS, et al.Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2016;91(9):E341-E347.
112.
LightRW. Pleural effusions: The diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77(4):507-513.
113.
AzoulayESchellongowskiPDarmonM, et al.The Intensive Care Medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med. 2017;43(9):1366-1382.
